Voices
BOT+BAL Continues to Show Durable Clinical Benefit in MSS mCRC – Agenus
Agenus

BOT+BAL Continues to Show Durable Clinical Benefit in MSS mCRC – Agenus

Agenus, shared a post on LinkedIn:

“At ESMO GI 2026, Agenus announced three-year follow-up results from the fully enrolled Phase 1b cohort evaluating the investigational combination of botensilimab (BOT) and balstilimab (BAL) in patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC) without active liver metastases.

Among 123 patients, the combination demonstrated:

  • Median overall survival of 21.2 months
  • Three-year overall survival of 33%
  • 17% of patients remained alive and off all systemic anticancer therapy
  • No new safety signals were observed with extended follow-up

These data build on the two-year results presented at ESMO GI 2025.

Other articles about Colorectal Cancer on OncoDaily.

Agenus BAL Balstilimab Benjamin L. Schlechter BOT botensilimab cancer cancer immunotherapy Cancer research clinical oncology clinical trials colorectal cancer CTLA-4 Dana-Farber Cancer Institute ESMO Gastrointestinal Cancers Congress ESMO GI 2026 Gastrointestinal Oncology immunotherapy mCRC Metastatic colorectal cancer microsatellite stable MSS OncoDaily Oncology oncology drug development overall survival PD-1 Phase 1b